// Clankers Regulatory Services
You don't buy our time — you buy a finished document. Every service below is a defined deliverable, priced on request, produced by our team and personally reviewed by Carlos V. Rodriguez: 20+ years in regulatory affairs at Roche, Edwards Lifesciences and PPD/Thermo Fisher — Associate Director, RA Global Operations, and Swiss legal representative for Swissmedic clinical trial applications. EMA, FDA and Swissmedic procedures; CTAs, MAAs, variations and eCTD. That judgement is what you are paying for; the production line behind it is ours.
Not sure where your submission stands? Start with the free Submission Readiness Checker — five minutes, a scored result, and a gap list. Or take the weekly Regulatory Watch brief so the next change never surprises you.
PMS deadline: EMA's Product Management Service roadmap calls for manufacturer-data enrichment for all non-centrally authorised products in December 2026. The PMS Manufacturer-Data Sprint below prepares that work now.
eCTD v4.0: optional use for new centralised applications has been live since December 2025. EMA strongly recommends v4.0 for new centralised applications from Q1 2027, and it becomes mandatory for those applications from Q1 2028. The eCTD v4.0 Readiness Audit below finds your gaps before your first filing does.
EUDAMED deadline: devices first placed on the EU market before 28 May 2026 and still being sold must be registered in the UDI/Device module by 28 November 2026 — a Saturday, so Friday 27 November is the working deadline. The EUDAMED Registration Sprint below triages and prepares that registration; intake closes in stages from 20 November.
SS(C)P handover: under MDCG 2026-4 rev.1, uploading your Summaries of Safety and (Clinical) Performance to EUDAMED — the validated master plus its translations — moves from your notified body to you when the new functionality reaches Production, planned for December 2026. For devices already on the market, the MDCG guidance is to upload as soon as possible and no later than 27 March 2027. The SS(C)P Upload Readiness service below builds the register and the checks behind that upload.
The IRIS front door: EMA now runs the pre-submission phase of the centralised procedure through IRIS — eligibility and the letter of intent are a single submission type, and nothing can be submitted until a chain of registrations already holds. Eligibility is due between 18 and (at latest) 7 months before you file, so a sponsor filing in June 2027 reaches its 7-month point this month. The IRIS Pre-Submission Readiness service below audits the chain and builds the eligibility package against that clock.
Electronic product information is becoming the EMA standard, and most SmPCs were never written to survive structuring. We map your current product information to the ePI (FHIR) structure before you commit to a conversion project.
You send us: your current SmPC and package leaflet (Word or PDF) for each product in scope, plus any existing structured-content work to build on.
Order ↓A plain-language summary of your trial results, written to the EU Clinical Trials Regulation's lay-summary requirements — Annex V content, genuine lay readability, neutral presentation of results — ready for CTIS.
You send us: your results synopsis or CSR synopsis, the protocol (or CTIS application number), and the intended submission date.
Order ↓Regulatory translation is not general translation: one wrong term in a contraindication is a deficiency letter. Our translations are produced and reviewed by people who write product information for a living, in the three languages we work in natively and professionally — Spanish, English and Japanese (one direction per order).
You send us: the source documents (Word preferred), the direction, and — for the QA tier — any company terminology list you work to.
Order ↓A senior audit of your planned EU submission before the agency sees it — the same review an experienced regulatory director would run internally, from outside your organisation.
You send us: your dossier structure (eCTD sequence outline or CTD table of contents), Module 1 documents, target submission date and procedure type.
Order ↓The revised CTIS transparency rules decide what of your trial becomes public, and when. We build the redaction position document by document, before the publication clock forces your hand.
You send us: the documents in scope (protocol, IB, ICF, synopsis — as available) and your CTIS trial number.
Order ↓Under EMA's Product Management Service (PMS) roadmap, marketing authorisation holders must enrich the structured manufacturer data for all their non-centrally authorised products in PMS in December 2026. For non-CAPs, that data comes from the MAH's own Article 57 / XEVMPD submissions — errors included. We reconcile every manufacturer and manufacturing business operation against the authorised record and hand back an entry-ready worksheet. Your team enters the data in its own PMS account; we never ask for PMS or PLM credentials.
You send us: your PMS PUI and/or XEVMPD exports, authorised non-CAP product list, current manufacturing authorisations and dossier manufacturer sections, and your OMS organisation list. Never send login credentials. Anything that cannot be traced to an authorised source is flagged for your confirmation — never filled in from assumption.
Order ↓EMA opened optional eCTD v4.0 use for new centralised marketing authorisation applications in December 2025. From Q1 2027 the format is strongly recommended for those applications; from Q1 2028 it is mandatory for them. Version 3.2.2 keeps working during the transition — which is exactly why readiness slips: v4.0 describes a whole submission in a single structured message, identifies documents so previously submitted content can be referenced instead of resubmitted, tracks lifecycle changes against each document's context of use, and classifies metadata with controlled vocabularies. Whether that helps you or hurts you is decided by things you control now: how granular your documents are, which of them can be reused, how clean your lifecycle history is, and whether your publishing route has actually been checked against the current EU validation criteria (v1.1, applicable since July 2026). We audit exactly that and hand back a dated, gap-by-gap readiness plan. We audit — we do not publish or submit: you and your publisher keep the tools and make the submission.
You send us: your planned-application list with intended filing dates and routes (centralised / non-centralised), your existing centralised products with their eCTD version and sequence history, the document inventory for the planned application, and your publishing tool/vendor name and version. Never send gateway or publishing-system login credentials. Every finding is traced to your own submission history and document inventory — where your records cannot show how a document was lifecycled, the gap is stated as a gap, never reconstructed from assumption.
Order ↓Four EUDAMED modules have been mandatory since 28 May 2026. Devices — Regulation and legacy — that were first placed on the EU market before that date and are still being placed must be registered in the UDI/Device module by 28 November 2026. That date is a Saturday; Friday 27 November is the last working day. Two traps catch portfolios out: an actor registration (an SRN) validates the economic operator but does not register a single device, and the 28 May 2027 date that circulates in planning spreadsheets belongs to certificates — your notified body's backlog, not your device records. New device identifiers have no grace period at all: they must be registered before their first unit is placed. We triage your portfolio device identifier by device identifier against exactly those rules, reconcile the Basic UDI-DI, UDI-DI and EMDN data across label, IFU and technical documentation before anything is uploaded, and prepare upload-ready tables in EUDAMED field order. The work is led by a regulatory consultant with 20+ years across medicines and devices, including seven years in medical devices at Edwards Lifesciences. Because the calendar is what it is, intake closes in stages, and we say so plainly: Sprint Partner intake closes Friday 20 November 2026; Registration Readiness Pack intake closes Tuesday 24 November 2026; Portfolio Triage is available until Wednesday 25 November 2026. After the deadline a triage converts, honestly, into a written risk position and remediation plan at the same fee — no Tier 1 bought late is promised a filing by 27 November.
You send us: your device list (trade name, Basic UDI-DI and UDI-DI where assigned, EMDN code), your actor registration / SRN status, labels and IFUs for the devices in scope, and the first-placing and continued-placing evidence per device. Boundary: the manufacturer files from its own validated actor account and must never send EUDAMED credentials; we do not act as EU Authorised Representative or PRRC. We prepare and advise — the filing, and the legal responsibility for it, stays with you.
Order ↓Your notified body is about to hand you a job it has always done for you. For implantable and Class III devices, and for Class C and D diagnostics, the Summary of Safety and Clinical Performance (SSCP) / Summary of Safety and Performance (SSP) is the public face of your clinical evidence — and until now your notified body uploaded the validated master to EUDAMED when it registered your certificate, without translations. Under MDCG 2026-4 rev.1 (October 2026) that changes: once the new functionality reaches EUDAMED Production — planned for December 2026, and stated here as planned, not live — the manufacturer uploads the validated master and its translations itself, and the notified body simply marks which summary it validated, device by device. For devices already on the market before mandatory use, the MDCG position is that manufacturers “should upload as soon as possible and no later than 27 March 2027”. That is guidance in a non-binding position paper, not a legal deadline — but the work underneath it is real either way, and 27 March 2027 is a Saturday, so Friday 26 March is the working target. What decides whether March is easy is work that can be done now: knowing, device by device, which summary was validated, in which language, whether the file you hold is that validated version, whether your translations match it and cover the markets you actually sell in, and whether your upload sequence is aligned with your notified body's certificate timeline. This is a different layer from device registration — the EUDAMED Registration Sprint above handles the device records; this service handles the validated summaries that sit on top of them, and the two are quoted separately. The work is led by a regulatory consultant with 20+ years across EMA, FDA and Swissmedic, including seven years in medical devices at Edwards Lifesciences.
You send us: your device list with Basic UDI-DIs, classes and notified body per device, the validated master files with the language each was validated in, your full translation set, the Member States each device is sold in, and your notified-body certificate references. Boundary: you upload yourselves, from your own EUDAMED actor account — never send us EUDAMED credentials. We do not validate summaries (validation is your notified body's alone) and we never edit a validated master; if one needs changing, that is a finding for the notified-body route, and we flag it rather than fix it. We are not your EU Authorised Representative.
Order ↓Your centralised filing is decided months before you file — in a platform many sponsors open for the first time with the clock already running. EMA now runs the pre-submission phase of the centralised procedure through IRIS: eligibility for the centralised procedure and the letter of intent are a single IRIS submission type (“Eligibility and letter of intent”), rapporteur appointments and pre-submission interactions run through the same platform, and post-authorisation life — variations, transfers, renewals — has been managed in IRIS since 2025, with the legacy system being decommissioned. Before IRIS accepts anything, a chain of prerequisites must already hold: an EMA account with the right IRIS role, your organisation listed in OMS, an EMA customer account number, your substances registered in SMS, and a valid Research Product Identifier (RPI) held by the right organisation. None of it is difficult. All of it is sequential — a substance registration that needs a new substance entry may take up to five working days, on EMA's own guidance — and the clock it feeds is long: eligibility is due between 18 and (at latest) 7 months before you file, the letter of intent around 7 months before, the pre-submission meeting — the one structured chance to get EMA's procedural advice — 6 to 7 months before, and re-confirmation of the submission date 3 to 2 months before. A sponsor filing in June 2027 reaches its 7-month point this month, in November 2026. Sponsors who start the chain when the filing plan starts arrive at that meeting ready; sponsors who discover it late arrive with registrations pending and questions unasked. Eligibility is not a formality, either: the request carries a justification and a draft SmPC, CHMP confirms eligibility, and a weak or late justification can put an application on the wrong procedural route entirely. We run the chain for you — a prerequisites audit with lead times, the eligibility justification built from your own documents, a dated clock plan worked backwards from your filing date, and meeting preparation — led by a regulatory affairs consultant with 20+ years across EMA, FDA and Swissmedic procedures, including RA operations at associate-director level and centralised procedures throughout.
You send us: your intended filing date and route, the product and any designation status (orphan, PRIME, agreed PIP), your organisation's existing EMA footprint (account and roles, OMS record, customer account number), your substance list, your RPI status and holder, and any prior EMA correspondence with its identifiers — record references or screenshots from your own accounts only. Boundary: you file everything yourselves, from your own IRIS account — we never hold EMA or IRIS credentials, never log in as you and never submit on your behalf; we prepare, check and sequence. No eligibility outcome is promised, ever: CHMP decides eligibility, and what we guarantee is a complete, correctly-grounded request filed on time.
Order ↓Your SmPC/PIL mapped to the EMA ePI (FHIR) structure, a gap list, and a structured-content preparation pack. Within 7 business days of receiving your documents.
A CTIS-ready lay summary of your trial results, written to the CTR Annex V requirements. Within 7 business days of receiving your synopsis.
One SmPC translated between Spanish, English and Japanese, QRD terminology, consistency-checked. Within 5 business days.
SmPC, package leaflet and labelling, one direction, cross-document consistency checks. Within 7 business days.
The Full PI Set plus a written regulatory QA report: QRD conformity, terminology decisions, readability notes, flagged source issues. Within 10 business days.
A senior audit of your planned CTA or MAA: dossier structure, Module 1, eCTD readiness, and a prioritised fix list in a written report. Within 10 business days.
Document-by-document redaction proposals, CCI justification notes and a deferral strategy summary. Within 7 business days.
Full non-CAP record inventory, the December 2026 scope in writing, mismatch count by type, and a dated work-back plan. Within 5 business days.
Triage plus traced reconciliation and a PUI entry-ready worksheet for up to 25 products, with OMS gaps and an issue log. Within 10 business days.
The Worksheet Pack for up to 75 products under one MAH, MRP/DCP families reconciled consistently, plus the reusable template and June 2027 pack-size skeleton. Within 15 business days.
The current EMA timeline memo, an inventory of what the v4.0 transition touches for you, a gap count against the v1.1 validation-criteria themes and Controlled Vocabularies v3, and a dated readiness plan. Within 5 business days.
Triage plus the full audit for one planned new centralised MAA: document inventory, granularity review, reuse register, vocabulary mapping sheet, publishing-route check and test-submission plan. Within 10 business days.
The First-MAA audit across a portfolio, plus a forward-compatibility watch file for every existing v3.2.2 lifecycle product, a v4.0 document-practice standard, and a 2027 filing calendar. Within 15 business days.
Every device identifier classified against the 28 November 2026 transitional deadline, the pre-placement rule and the out-of-scope cases — severity-ranked, with the evidence per conclusion. Within 3 business days. Intake closes 25 November 2026.
Triage plus Basic UDI-DI / UDI-DI / EMDN reconciliation across label, IFU and technical documentation, and upload-ready data tables in EUDAMED field order. One legal manufacturer, up to 25 device identifiers. Within 7 business days. Intake closes 24 November 2026.
The Readiness Pack run as a live sprint to the 27 November 2026 working deadline: daily register control, upload-sequence planning with your team, query handling and post-filing public-record verification. Intake closes 20 November 2026.
A device-by-device register of your validated masters, validated languages, translation coverage and EUDAMED state — each line marked ready, gap or notified-body-dependent — plus a dated handover plan to Friday 26 March 2027. Within 5 business days.
The Audit plus validated-version identity checks, translation-congruence checks (Spanish natively) and a patient-section plain-language check for up to 10 summaries, with the upload sequence and notified-body correspondence drafted. Within 10 business days.
The Pack plus accompaniment from the Production go-live to upload: preparation sessions with your team (you click, we guide), post-upload public-record verification per device, and the annual-update register set up.
A prerequisites audit of the IRIS chain (EMA account and role, OMS listing, customer account number, SMS substances, RPI), the eligibility position memo, and a dated clock plan worked backwards from your filing date. Within 5 working days.
The Triage plus the eligibility justification drafted from your own documents (every claim traced to its source), the draft-SmPC alignment check, letter-of-intent content, the chain register closed out, and a meeting briefing pack outline. One revision round. Within 10 business days.
The Package Build plus meeting preparation and rehearsal, the outcome converted into a filing-plan amendment, re-confirmation handled on the clock plan, optional accelerated-assessment / conditional-MA / PRIME requests prepared, and a final-month validation-readiness check.
Secure checkout by Stripe · Pricing on request — no subscription, no hourly billing · Turnarounds run from the day we receive your documents
A clean deliverable does not guarantee an agency outcome — anyone who promises that is selling you something. What we guarantee is the work itself: documents and audits produced to the standard of a regulatory department that has run these procedures for two decades, reviewed personally before they reach you. If a service is not right for your situation, we will tell you before we start, not after you've paid for the wrong thing — write to us first if you're unsure.
Keep current between submissions with the Regulatory Watch weekly brief — what changed at EMA, FDA and Swissmedic, and who must act. Sample issue free.
© 2026 Clankers.today · Regulatory Services are professional document and advisory services; they do not replace your regulatory department or legal advice, and agency decisions remain with the agencies. Questions: support@clankers.today · Terms